Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1964 1
1971 2
1972 2
1973 2
1974 3
1975 5
1976 5
1977 3
1978 5
1979 10
1980 16
1981 12
1982 12
1983 19
1984 23
1985 18
1986 18
1987 19
1988 31
1989 36
1990 22
1991 34
1992 37
1993 29
1994 42
1995 36
1996 39
1997 36
1998 66
1999 65
2000 65
2001 63
2002 60
2003 61
2004 64
2005 87
2006 80
2007 91
2008 105
2009 122
2010 134
2011 143
2012 168
2013 167
2014 173
2015 168
2016 178
2017 177
2018 174
2019 188
2020 200
2021 174
2022 170
2023 181
2024 65

Text availability

Article attribute

Article type

Publication date

Search Results

3,475 results

Results by year

Filters applied: . Clear all
Page 1
Malignant Pleural Effusion and Its Current Management: A Review.
Skok K, Hladnik G, Grm A, Crnjac A. Skok K, et al. Medicina (Kaunas). 2019 Aug 15;55(8):490. doi: 10.3390/medicina55080490. Medicina (Kaunas). 2019. PMID: 31443309 Free PMC article. Review.
It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. ...Treatment …
It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and mal …
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Hendry S, et al. Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Adv Anat Pathol. 2017. PMID: 28777143 Free PMC article. Review.
In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary bra …
In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, i …
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME. Anevlavis S, et al. Clin Respir J. 2018 Mar;12(3):839-847. doi: 10.1111/crj.12597. Epub 2017 Jan 11. Clin Respir J. 2018. PMID: 27997741 Review.
OBJECTIVES: To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleural infection, treatment of pneumothorax, and diagnosis and pleurodesis of malignant pleural mesothelioma. Also to describe the newer t …
OBJECTIVES: To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleura …
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z. Miettinen M, et al. Am J Surg Pathol. 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. Am J Surg Pathol. 2014. PMID: 24145643 Free PMC article.
Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary gland (43%), and pancreatic (37%) ductal carcinomas, whereas frequency of expression in adenocarcinomas of lung, stomach, colon, endometrium, ovary, and prostate was <10%. ...
Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary gland (43%), and pancreatic (37%) ductal carc …
Asbestos in Asia.
Leong SL, Zainudin R, Kazan-Allen L, Robinson BW. Leong SL, et al. Respirology. 2015 May;20(4):548-55. doi: 10.1111/resp.12517. Epub 2015 Mar 29. Respirology. 2015. PMID: 25819225 Free article. Review.
Numerous factors ranging from political and economic to the lack of understanding of asbestos and the management of asbestos-related lung disease are keys to this observed trend. Awareness of these factors combined with early intervention may prevent the predicted A …
Numerous factors ranging from political and economic to the lack of understanding of asbestos and the management of asbestos-related lung di …
Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P, Martorana F, Manzella L, Stella S. Vigneri P, et al. Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Future Oncol. 2015. PMID: 26638920 Review.
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that will allow a timely diagnosis; display prognostic value; and, predict the response to pharmacological agents employed for the treatmen …
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that w …
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I. Bibby AC, et al. Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Eur Respir Rev. 2016. PMID: 27903668 Free PMC article. Review.
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next fe …
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. T …
The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma.
Davidson B. Davidson B. Cytopathology. 2011 Feb;22(1):5-21. doi: 10.1111/j.1365-2303.2010.00829.x. Epub 2010 Nov 30. Cytopathology. 2011. PMID: 21114695 Review.
Malignant mesothelioma and ovarian/peritoneal serous carcinoma are two of the most common tumours affecting the serosal cavities. ...This review will present current data regarding the diagnostic and biological aspects of malignant mesothelioma and ovarian/peritonea …
Malignant mesothelioma and ovarian/peritoneal serous carcinoma are two of the most common tumours affecting the serosal cavities. ... …
Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
Yeap BY, De Rienzo A, Gill RR, Oster ME, Dao MN, Dao NT, Levy RD, Vermilya K, Gustafson CE, Ovsak G, Richards WG, Bueno R. Yeap BY, et al. J Thorac Oncol. 2021 Nov;16(11):1925-1935. doi: 10.1016/j.jtho.2021.06.014. Epub 2021 Jul 6. J Thorac Oncol. 2021. PMID: 34242791 Free PMC article.
INTRODUCTION: Prognostic models for malignant pleural mesothelioma have been limited to demographics, symptoms, and laboratory values. We hypothesize higher accuracy using both tumor and patient characteristics. The mesothelioma prognostic test (MPT) and molecular s …
INTRODUCTION: Prognostic models for malignant pleural mesothelioma have been limited to demographics, symptoms, and laboratory values …
3,475 results